Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Squashed Takeovers And Positive Test Results Propelling These Stocks Higher

Page 1 of 2

Three stocks are making some major noise in today’s trading session, with gains of over 15% for all three. The companies behind the stocks making these gargantuan gains are Bellerophon Therapeutics Inc (NASDAQ:BLPH), Synaptics, Incorporated (NASDAQ:SYNA), and Depomed Inc (NASDAQ:DEPO), and we’ll run through the action on each and their accompanying hedge fund sentiment.

Biotech Biochemical Stocks 3

Let’s start with Bellerophon Therapeutics Inc (NASDAQ:BLPH), which we’ve now covered three times in the past few days owing to the extreme volatility in the stock. On September 25 it enjoyed a massive swing to the upside of about 69% following the release of positive data related to its Phase 2 study of INOpulse, for the treatment of Pulmonary Arterial Hypertension. However, just a few days later it was back in the news due to its stock heading sharply in the other direction, giving back most of its Friday gains in the first two trading sessions of this week, as the market seemingly decided that the gains were an overreaction, and that despite the positive news, the market for the treatment may not be overly big.

Yet here we are on Wednesday and momentum appears to have swung back to the buy side again, as shares are up by a touch over 25%. The push today follows more information being released related to INOpulse, at the European Respiratory Society (ERS) International Congress 2015 in Amsterdam. The newly-released data was from a small trial of six patients with pulmonary hypertension, each of which was given an acute dose of INOpulse nitric oxide. The results showed increased blood flow in the lungs of all six patients, while oxygen saturation was preserved.

Hedge funds we track were quite positive about Bellerophon Therapeutics Inc (NASDAQ:BLPH), owning 44.90% of the biotech’s shares as of June 30. In all, six funds we track had positions valued at $45.99 million at that time. Also noteworthy is the fact that Julian Baker and Felix Baker’s Baker Bros. Advisors was the top shareholder of those six, with 350,000 shares at the end of June. The stock picks of the healthcare fund have been exceptional this year, ranking it as one of the top funds in our database.

Follow Bellerophon Therapeutics Inc. (NASDAQ:BLPH)
Trade (NASDAQ:BLPH) Now!

Most investors don’t understand hedge funds and indicators that are based on hedge funds’ activity. They ignore hedge funds because of their recent poor performance in the bull market. Our research indicates that hedge funds partly underperformed because they aren’t 100% long. Hedge funds’ fees are also very large compared to the returns generated, which reduces the net returns delivered to investors. We uncovered through extensive research that historically, hedge funds’ long positions in certain stocks actually outperformed the market greatly, and it has held true to this day. For instance, the 15 most popular small-cap stocks among funds has beaten the S&P 500 Index by more than 60 percentage points since the end of August 2012. These stocks returned a cumulative of 118% vs. less than 58% for the S&P 500 Index (read the details). That’s why we believe investors should pay attention to what hedge funds are buying, particularly in the small-cap sector, rather than what their net returns are, which the media primarily focuses on.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!